Baseline Expression of Immune Gene Modules in Blood is Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease Patients.

"Conflicts of Interest Mark Reppell, Nizar Smaoui, Jeffrey F. Waring, Valerie Pivorunas, and Heath Guay are employees of AbbVie and may own stock and/or options. Simeng Lin reports non-financial support from Pfizer outside the submitted work. James R. Goodhand reports grants from F. Hoffmann-La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV, and non-financial support from Immundiagnostik outside the conduct of the study. Nicholas A. Kennedy reports grants from F. Hoffmann-La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV, and non-financial support from Immundiagnostik; grants and non-financial support from AbbVie, grants and personal fees from Celltrion, personal fees and non-financial support from Janssen, personal fees from Takeda, and personal fees and non-financial support from Dr Falk, outside the submitted work. Tariq Ahmad reports grants and non-financial support from F. Hoffmann-La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV, and non-financial support from Immundiagnostik; personal fees from Biogen Inc, grants and personal fees from Celltrion Healthcare, personal fees and non-financial support from Immundiagnostik, personal fees from Takeda, personal fees from ARENA, personal fees from Gilead, personal fees from Adcock Ingram Healthcare, personal fees from Pfizer, personal fees from Genentech, and non-financial support from Tillotts, outside the submitted work. Carl A. Anderson has received consultancy or lectureship fees from Genomics plc, BridgeBio, and GSK. The remaining authors have no conflicts of interest to report."

"Funding PANTS is an investigator-led study funded by CORE [renamed Guts UK in 2018], the research charity of the British Society of Gastroenterology, and by unrestricted educational grants from AbbVie Inc, USA; Merck Sharp & Dohme Ltd, UK; NAPP Pharmaceuticals Ltd, UK; Pfizer Ltd, USA; Celltrion Healthcare, South Korea; and Cure Crohn’s Colitis [Scottish IBD Charity]. The sponsor of the PANTS study is the Royal Devon and Exeter National Health Service Foundation Trust. Data generation, sequencing, and sample analysis were funded by AbbVie. This research was funded in whole, or in part, by the Wellcome Trust [grant numbers 206194, 108413/A/15/D, and 222850/Z/21/Z]. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission."

"The South West Research Ethics committee approved the study [Research Ethics Committee reference: 12/SW/0323] in January 2013. Patients were included after providing informed, written consent. The study is registered with ClinicalTrials.gov identifier NCT03088449 and the protocol is available at https://www.ibdresearch.co.uk/pants/."